NCT06783816

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

A Multicenter, Single Arm, Open Label Clinical Study on the Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Shanxi Bethune Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.

Detailed description

The main objective is to evaluate the safety and efficacy of a novel CAR-T therapy that co expresses IL-15 in malignant hematological tumors. The secondary objective is to investigate the in vivo survival time of the novel CAR-T co expressing IL-15 and the activation and proliferation of a novel CAR-T co expressing IL-15 in vivo.

Conditions

• Acute Lymphocytic Leukemia
• Lymphoma,Non-Hodgkin
• Relapsed Refractory Multiple Myeloma

Interventions

Type	Name	Description
DRUG	chimeric antigen receptor gene modified T cells	The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.

Timeline

• Start date: 2023-12-01
• Primary completion: 2028-06-01
• Completion: 2028-06-01
• First posted: 2025-01-20
• Last updated: 2025-01-20

Locations

1 site across 1 country: China